FDA is hosting a virtual Information Session on Generic Drug Research Needs & Opportunities for fiscal year (FY) 2026 on Wednesday, January 21, 2026.
Similar Posts
E2D(R1) Post-Approval Safety Data: Definitions and Standards for Management and Reporting of Individual Case Safety Reports
E2D(R1) Post-Approval Safety Data: Definitions and Standards for Management and Reporting of Individual Case Safety ReportsDisseminated Coccidioidomycosis: Developing Drugs for Treatment
Disseminated Coccidioidomycosis: Developing Drugs for TreatmentWeight Loss, Male Enhancement and Other Products Sold Online or in Stores May Be Dangerous
Consumers cannot be confident that certain products, including weight loss and male enhancement products, sold on online marketplaces like Amazon and eBay or in stores, are safe to use.FDA Provides Guidance on Remote Interactive Evaluations for Oversight of Drug Facilities During COVID-19
FDA releases guidance on how remote interactive evaluations will be requested by FDA and conducted for the duration of COVID-19 at drug facilities.BSO, LLC. Golden, CO. 483 issued 06/27/2025
Task Description Request Please post to the OII FOIA Electronic Reading Room
Record Date 06/27/2025
Short Title (70 char) BSO, LLC. Golden, CO. 483 issued 06/27/2025
FEI Number 3030548360
Firm Name BSO, LLC
Record Type 483
State CO
Establishment Type Outsourcing FacilityDr. Reddy’s Laboratories Limited | 12/12/2025 | 483
Dr. Reddy’s Laboratories Limited | 12/12/2025 | 483